Browsing category:

Patent Expiration 2019


As a formidable and known nucleoside analogue, Telbivudine is one of a few oral treatments to combat HBeAg positive and negative chronic hepatitis B. Known as the brand name Tyzeka, Telbivudine has a patent expiration of August 10, 2019.  While the use of Telbivudine has been extremely successful in the United States, other countries around[…]

Read More

Testosterone CAS# 58-22-0, made the pharmaceutical headlines mid June 2013 when study findings were announced touting testosterone for perceived pain relief. Data presented on June 17, 2013, at the Endocrine Society’s 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. The study funded by Abbott Pharmaceuticals, involved 84 men who[…]

Read More

Liraglutide CAS No: 204656-20-2 On June 17, 2013 Endocrine Today reported at the ENDO 2013 meeting that Liraglutide demonstrated success as a weight loss treatment. Combined with the antidiabetic drug Metformin, Liraglutide was administered on a short term basis to women with polycystic ovary syndrome who were considered obese. “Obesity is a great problem in[…]

Read More

Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing  the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]

Read More

As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]

Read More

Clopidogrel Bisulfate, also known as the brand name anticoagulant medication Plavix, continues to impress with its safety profile. A study released at the end of March 2013 revealed that patients set to undergo percutaneous coronary intervention could successfully continue their regimen of Clopidogrel during this time. Caution was extended from the study investigators, which took[…]

Read More